Clinical Trial Update: Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations [Phase 3]

View source ↗

Summary

Phase 3 trial of olaparib maintenance versus placebo in platinum-sensitive relapsed ovarian cancer with sBRCAm or HRR gene mutations has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Platinum Sensitive Relapsed Ovarian Cancer | Phase 3 | Status: WITHDRAWN